NFKB1 and infection: However, based on adverse effects like enhanced susceptibility to infection by long‐term inhibition, neither TNF‐α nor NF‐κB are suitable pharmacological targets to decrease inflammaging (Ha et al., 2022; Leone et al., 2023).